title: RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study.
abstract: BACKGROUND
  Optimum dose ratios of rimabotulinumtoxinB (BTX-B) and onabotulinumtoxinA (BTX-A) have not been determined for forehead wrinkles.
  
  
  OBJECTIVE
  To compare the efficacy and safety of BTX-B and BTX-A for the treatment of forehead lines.
  
  
  METHODS
  Twenty-two women (mean age, 40 years) with symmetrical moderate to severe forehead lines were randomized to receive single intramuscular injections of BTX-A and BTX-B on either side of the forehead, at a potency ratio of 1 : 70 or 1 : 100. Subjects were followed-up for 16 weeks. Four physicians evaluated patients' photographs according to the 4-point Facial Wrinkling Grade (FWG). Clinical Improvement Scale (CIS) was calculated by subtracting FWG score at each visit from that at baseline. Patient satisfaction scores and adverse events were also recorded.
  
  
  RESULTS
  Both BTX-A and BTX-B were effective for the treatment of forehead lines. At both potency ratios, BTX-A had a longer duration of action than BTX-B, while BTX-B led to faster improvement than BTX-A. There was no significant difference in CIS between 700 U and 1000 U BTX-B treatments. Adverse effects were mild and transient.
  
  
  CONCLUSIONS
  Both BTX-A and BTX-B were effective and well tolerated for the treatment of forehead wrinkles at potency ratios of 1 : 70 and 1 : 100.
authors.affiliation: Department of Dermatology, Seoul National University College of Medicine, Institute of Human-Environment Interface Biology, Seoul National University, Seoul, Korea.
authors.forename: D H
authors.initials: DH
authors.lastname: Lee
authors.forename: S M
authors.initials: SM
authors.lastname: Kang
authors.forename: A
authors.initials: A
authors.lastname: Feneran
authors.forename: C S
authors.initials: CS
authors.lastname: Youn
authors.forename: J K
authors.initials: JK
authors.lastname: Kim
authors.forename: S
authors.initials: S
authors.lastname: Cho
authors.forename: C H
authors.initials: CH
authors.lastname: Won
authors.forename: S E
authors.initials: SE
authors.lastname: Chang
authors.forename: M W
authors.initials: MW
authors.lastname: Lee
authors.forename: J H
authors.initials: JH
authors.lastname: Choi
authors.forename: K C
authors.initials: KC
authors.lastname: Moon
mesh_terms: D000328:Adult; D001905:Botulinum Toxins / Q000009:adverse effects / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004954:Esthetics; D005152:Facial Muscles / Q000187:drug effects; D005260:Female; D005546:Forehead; D006801:Humans; D007273:Injections, Intramuscular; D007723:Korea; D008875:Middle Aged; D017060:Patient Satisfaction; D010865:Pilot Projects; D011446:Prospective Studies; D018570:Risk Assessment; D016037:Single-Blind Method; D015595:Skin Aging / Q000187:drug effects*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A